ELAN

As of 2026-09-11, ELAN scores 49out of 100 on QNTM’s five-factor quantitative model, a moderate conviction reading. The score blends momentum, quality, volume, value and sentiment, then adjusts for the current macro regime. ELAN trades at $23.17, within its fair-value band.

ELAN scores 49 out of 100 on QNTM's five-factor model — a moderate reading — neither strongly favored nor flagged for weakness at 49. Its strongest factor is value at 89 (exceptional), where it screens cheap on the model's valuation inputs, followed by volume at 43. The weakest is momentum at 37, where price trend is the soft spot. Among Healthcare stocks it ranks in roughly the top 35% of the Healthcare names the model scores.

On valuation, ELAN is priced in the upper part of its recent range. The profile is lopsided — a few factors carry it while others drag, so the composite masks real disagreement underneath. The blended composite before the macro overlay was 50. Same-sector names the model rates nearby include HALO, THC, HNGE.

This is a descriptive factor read on ELAN, recomputed each trading day and shown with its reasoning — not a recommendation to buy, hold or sell. The score reflects where ELAN sits on the model's measures today, and can change as new data arrives.

FACTOR BREAKDOWN

VALUATION RANGE

QNTM’s descriptive fair-value band for ELAN runs $15.68–$26.06. Current price $23.17 sits within its fair-value band. This is valuation context, not a price target.

OTHER HEALTHCARE NAMES

QNTM provides quantitative model outputs for informational and educational purposes only. It is not investment advice and QNTM is not a registered investment adviser. Scores are rankings, not buy/sell recommendations. Data as of 2026-09-11.